34322703|t|Venetoclax plus low-dose cytarabine in Japanese patients with untreated acute myeloid leukaemia ineligible for intensive chemotherapy.
34322703|a|BACKGROUND: In a multinational phase 3 trial (VIALE-C), venetoclax plus low-dose cytarabine prolonged overall survival vs placebo plus low-dose cytarabine in patients with newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy, although it was not statistically significant. Herein, we assess the benefit of venetoclax plus low-dose cytarabine in the Japanese subgroup of VIALE-C patients (n = 27). METHODS: VIALE-C, a randomized (2:1), double-blind study (NCT03069352), enrolled untreated patients (>=18 years) with acute myeloid leukaemia. Patients received venetoclax (600 mg days 1-28, 4-day ramp-up in cycle 1) or placebo in 28-day cycles with low-dose cytarabine (20 mg/m2 days 1-10). The primary endpoint was median overall survival. RESULTS: In the Japanese subgroup, at a 6-month follow-up from the primary analysis, median overall survival for venetoclax (n = 18) and placebo (n = 9), plus low-dose cytarabine, was 4.7 and 8.1 months, respectively (hazard ratio, 0.928, 95% confidence intervals : 0.399, 2.156). The rate of complete remission plus complete remission with incomplete blood count recovery was higher with venetoclax plus low-dose cytarabine (44.4%) vs placebo plus low-dose cytarabine (11.1%). All patients experienced at least 1 adverse event. The most common grade >=3 adverse events with venetoclax or placebo, plus low-dose cytarabine, were febrile neutropenia (50.0% vs 44.4%, respectively) and thrombocytopenia (27.8% vs 44.4%, respectively). Serious adverse events were reported in 50.0 and 33.3% of patients in the venetoclax and placebo, plus low-dose cytarabine arms, respectively; pneumonia was the most common (22.2% each). CONCLUSIONS: Limited survival benefit in the Japanese subgroup can be attributed to small patient numbers and to baseline imbalances observed between treatment arms, with more patients in the venetoclax plus low-dose cytarabine arm presenting poor prognostic factors. Venetoclax plus low-dose cytarabine was well tolerated in Japanese patients with acute myeloid leukaemia ineligible for intensive chemotherapy.
34322703	0	10	Venetoclax	Chemical	MESH:C579720
34322703	25	35	cytarabine	Chemical	MESH:D003561
34322703	48	56	patients	Species	9606
34322703	72	95	acute myeloid leukaemia	Disease	MESH:D054218
34322703	181	188	VIALE-C	Disease	OMIM:211750
34322703	191	201	venetoclax	Chemical	MESH:C579720
34322703	216	226	cytarabine	Chemical	MESH:D003561
34322703	279	289	cytarabine	Chemical	MESH:D003561
34322703	293	301	patients	Species	9606
34322703	323	346	acute myeloid leukaemia	Disease	MESH:D054218
34322703	466	476	venetoclax	Chemical	MESH:C579720
34322703	491	501	cytarabine	Chemical	MESH:D003561
34322703	530	537	VIALE-C	Disease	OMIM:211750
34322703	538	546	patients	Species	9606
34322703	566	573	VIALE-C	Disease	OMIM:211750
34322703	648	656	patients	Species	9606
34322703	675	698	acute myeloid leukaemia	Disease	MESH:D054218
34322703	700	708	Patients	Species	9606
34322703	718	728	venetoclax	Chemical	MESH:C579720
34322703	816	826	cytarabine	Chemical	MESH:D003561
34322703	1012	1022	venetoclax	Chemical	MESH:C579720
34322703	1067	1077	cytarabine	Chemical	MESH:D003561
34322703	1288	1298	venetoclax	Chemical	MESH:C579720
34322703	1313	1323	cytarabine	Chemical	MESH:D003561
34322703	1357	1367	cytarabine	Chemical	MESH:D003561
34322703	1381	1389	patients	Species	9606
34322703	1474	1484	venetoclax	Chemical	MESH:C579720
34322703	1511	1521	cytarabine	Chemical	MESH:D003561
34322703	1528	1547	febrile neutropenia	Disease	MESH:D064147
34322703	1583	1599	thrombocytopenia	Disease	MESH:D013921
34322703	1690	1698	patients	Species	9606
34322703	1706	1716	venetoclax	Chemical	MESH:C579720
34322703	1744	1754	cytarabine	Chemical	MESH:D003561
34322703	1775	1784	pneumonia	Disease	MESH:D011014
34322703	1909	1916	patient	Species	9606
34322703	1995	2003	patients	Species	9606
34322703	2011	2021	venetoclax	Chemical	MESH:C579720
34322703	2036	2046	cytarabine	Chemical	MESH:D003561
34322703	2087	2097	Venetoclax	Chemical	MESH:C579720
34322703	2112	2122	cytarabine	Chemical	MESH:D003561
34322703	2154	2162	patients	Species	9606
34322703	2168	2191	acute myeloid leukaemia	Disease	MESH:D054218
34322703	Positive_Correlation	MESH:D003561	MESH:D013921
34322703	Negative_Correlation	MESH:D003561	MESH:D054218
34322703	Negative_Correlation	MESH:C579720	MESH:D054218
34322703	Positive_Correlation	MESH:D003561	MESH:D064147
34322703	Positive_Correlation	MESH:C579720	MESH:D013921
34322703	Cotreatment	MESH:C579720	MESH:D003561
34322703	Negative_Correlation	MESH:C579720	OMIM:211750
34322703	Positive_Correlation	MESH:C579720	MESH:D064147

